Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Adverse Event Reporting and Recordkeeping for Dietary Supplements as Required by the Dietary Supplement and Nonprescription Drug Consumer Protection Act, 53252-53254 [E8-21454]
Download as PDF
53252
Federal Register / Vol. 73, No. 179 / Monday, September 15, 2008 / Notices
TABLE 1—ESTIMATED ANNUAL REPORTING BURDEN1
No. of
Respondents
Reports of serious adverse drug events (21
U.S.C. 379aa((b) and (c))
Annual
Frequency per
Response
50
Total Annual
Responses
250
Hours Per
Response
12,500
Total Hours
2
Total
25,000
25,000
1 There
are no capital costs or operating and maintenance costs associated with this collection of information.
The guidance also recommends that
responsible persons maintain records of
efforts to obtain the minimum data
elements for a report of a serious
adverse drug event and any followup
reports. Although the guidance
document does not provide
recommendations on all the
recordkeeping activities required under
section 760(e) of the act, we are
providing an estimate for this burden.
Historically, serious adverse event
reports comprise approximately twothirds, and nonserious adverse event
reports comprise approximately onethird, of the total number of
postmarketing adverse event reports
associated with drugs and biologic
therapeutics (except vaccines) received
by FDA. Based on this generalization,
we estimate the total annual records to
be approximately 20,000 records per
year, and the number of respondents to
be approximately 200. We also estimate
that it takes approximately 5 hours to
maintain each record.
TABLE 2.— ESTIMATED ANNUAL RECORDKEEPING BURDEN1
No. of
Recordkeepers
Annual
Frequency per
Recordkeeping
200
100
Recordkeeping (21 U.S.C. 379aa(e)(1))
Total Annual
Records
Hours Per
Record
20,000
Total
100,000
are no capital costs or operating and maintenance costs associated with this collection of information.
Therefore, the estimated annual
reporting burden for this information
collection is 25,000 hours and the
estimated annual recordkeeping burden
is 100,000 hours.
Dated: September 8, 2008.
Jeffrey Shuren,
Associate Commissioner for Policy and
Planning.
[FR Doc. E8–21345 Filed 9–12–08; 8:45 am]
BILLING CODE 4160–01–S
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2007–D–0372] (formerly
Docket No. 2007D–0388)
mstockstill on PROD1PC66 with NOTICES
5
100,000
1 There
Agency Information Collection
Activities; Submission for Office of
Management and Budget Review;
Comment Request; Adverse Event
Reporting and Recordkeeping for
Dietary Supplements as Required by
the Dietary Supplement and
Nonprescription Drug Consumer
Protection Act
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Total Hours
Notice.
VerDate Aug<31>2005
20:22 Sep 12, 2008
Jkt 214001
SUMMARY: The Food and Drug
Administration (FDA) is announcing
that a proposed collection of
information has been submitted to the
Office of Management and Budget
(OMB) for review and clearance under
the Paperwork Reduction Act of 1995.
DATES: Fax written comments on the
collection of information by October 15,
2008.
ADDRESSES: To ensure that comments on
the information collection are received,
OMB recommends that written
comments be faxed to the Office of
Information and Regulatory Affairs,
OMB, Attn: FDA Desk Officer, FAX:
202–395–6974, or e-mailed to
baguilar@omb.eop.gov. All comments
should be identified with the OMB
control number 0910–NEW and title,
‘‘Adverse Event Reporting and
Recordkeeping for Dietary Supplements
as Required by the Dietary Supplement
and Nonprescription Drug Consumer
Protection Act.’’ Also include the FDA
docket number found in brackets in the
heading of this document.
FOR FURTHER INFORMATION CONTACT:
Jonna Capezzuto, Office of Information
Management (HFA–710), Food and Drug
Administration, 5600 Fishers Lane,
Rockville, MD 20857, 301–796–3794.
SUPPLEMENTARY INFORMATION: In
compliance with 44 U.S.C. 3507, FDA
PO 00000
Frm 00065
Fmt 4703
Sfmt 4703
has submitted the following proposed
collection of information to OMB for
review and clearance.
Adverse Event Reporting and
Recordkeeping for Dietary Supplements
as Required by the Dietary Supplement
and Nonprescription Drug Consumer
Protection Act—(OMB Control Number
0910–NEW)
Description of Respondents:
Respondents to this collection of
information are manufacturers, packers,
and distributors of dietary supplements
marketed in the United States.
On December 22, 2006, the President
signed into law the Dietary Supplement
and Nonprescription Drug Consumer
Protection Act (DSNDCPA) (Public Law
109–462, 120 Stat. 3469). This law
amends the Federal Food, Drug, and
Cosmetic Act (the act) with respect to
serious adverse event reporting and
recordkeeping for dietary supplements
and non-prescription drugs marketed
without an approved application.
Under section 761(b)(1) of the act (21
U.S.C. 379aa–1(b)(1)), the manufacturer,
packer, or distributor whose name
(under section 403(e)(1) of the act (21
U.S.C. 343(e)(1))) appears on the label of
a dietary supplement marketed in the
United States is required to submit to
FDA any serious adverse event report it
receives regarding use of the dietary
E:\FR\FM\15SEN1.SGM
15SEN1
53253
Federal Register / Vol. 73, No. 179 / Monday, September 15, 2008 / Notices
supplement in the United States,
accompanied by a copy of the product
label. In addition, under section
761(c)(2) of the act, the submitter of the
serious adverse event report (referred to
in the statute as the ‘‘responsible
person’’) is required to submit to FDA
a followup report of any related new
medical information the responsible
person receives within 1 year of the
initial report. Under section 761(e)(1) of
the act, responsible persons are required
to maintain records related to dietary
supplement adverse event reports they
receive, whether or not the adverse
event is serious. These requirements
became effective on December 22, 2007.
As required by section 3(d)(3) of the
DSNDCPA, FDA is issuing guidance to
describe the minimum data elements for
serious adverse event reports for dietary
supplements. The draft guidance
entitled ‘‘Questions and Answers
Regarding Adverse Event Reporting and
Recordkeeping for Dietary Supplements
as Required by the Dietary Supplement
and Nonprescription Drug Consumer
Protection Act,’’ was issued October 15,
2007, and is consistent with FDA’s good
guidance practices regulation (21 CFR
10.115). The draft guidance discusses
how, when, and where to submit serious
adverse event reports for dietary
supplements and followup reports of
new medical information. In accordance
with the statutory requirements that
serious adverse event reports for dietary
supplements be submitted via
MedWatch (section 761(d) of the act)
and that FDA consolidate all
information related to a serious adverse
event into a single report (section
761(c)(3) of the act), the draft guidance
directs the responsible person to submit
serious adverse event reports on
MedWatch Form 3500A and to attach a
copy of the initial serious adverse event
report on Form 3500A as part of any
followup report of new medical
information. We are also providing
guidance on records maintenance and
access for serious and non-serious
adverse event reports and related
documents.
In the Federal Register of October 15,
2007 (72 FR 58313), FDA published a
60-day notice requesting public
comment on the information collection
provisions. FDA received one comment
related to the information collection.
The comment disagreed with FDA’s
proposed estimate of the annual
recordkeeping burden associated with
dietary supplement adverse events.
However, the commenter did not
provide an alternative estimate or
compelling information that the
estimate provided by FDA was not a
reasonable upper-bound estimate. Since
the receipt of the comment, the
mandatory reporting of serious adverse
events for dietary supplements to FDA
has come into effect (on December 22,
2007). Thus, FDA now has data on
mandatory dietary supplement adverse
event reports to use in revising our
reporting burden estimate. For the first
quarter of 2008 (January 1 to April 15),
FDA has received 214 mandatory
reports of serious adverse events related
to dietary supplements. Therefore, FDA
revises our annual burden estimate from
960 mandatory reports to 856
mandatory reports of serious adverse
events related to dietary supplements.
FDA requests comments on this
estimate.
FDA estimates the burden of this
collection of information as follows:
TABLE 1—ESTIMATED ANNUAL REPORTING BURDEN1
No. of
Respondents
Annual Frequency
per Response
Total Annual
Responses
Hours per
Response
Total Hours
Serious adverse event reports for
dietary supplements (21 U.S.C.
379aa–1(b)(1))
71.3333
12
856
2
1,712
Followup reports of new medical information (21 U.S.C. 379aa–
1(c)(2))
17.83333
12
214
1
214
Total
mstockstill on PROD1PC66 with NOTICES
1 There
1,926
are no capital costs or operating and maintenance costs associated with this collection of information.
FDA’s Center for Drug Evaluation and
Research estimates it will take
respondents a total of 2 hours to collect
information about a serious adverse
event associated with an over-thecounter drug marketed without an
approved application and report the
information to FDA on MedWatch Form
3500A. That time burden estimate is
based on FDA’s knowledge of the
adverse drug experience reports
submitted to the agency for
nonprescription drug products marketed
under an approved application,
including knowledge about the time
needed to prepare the reports. FDA
believes that the time for a dietary
supplement firm to collect information
about a serious adverse event associated
with a dietary supplement and report
the information to FDA will be
approximately the same, as MedWatch
VerDate Aug<31>2005
20:22 Sep 12, 2008
Jkt 214001
Form 3500A will be used in both cases;
therefore, we also estimate this time
burden at 2 hours per report. The
estimated total annual burden for
dietary supplement serious adverse
event reports is shown in row 1 of table
1 of this document.
If a firm that has submitted a serious
adverse event report receives new
medical information related to the
serious adverse event within 1 year of
submitting the initial report, the firm
must provide the new medical
information to FDA in a followup
report. Given our limited experience
with mandatory dietary supplement
adverse event reporting, we do not have
any information on the number of
followup reports of new medical
information that will be submitted to
FDA each year. We expect followup
medical information to be reported for
PO 00000
Frm 00066
Fmt 4703
Sfmt 4703
some percentage of the 856 serious
adverse event reports we estimate
receiving annually. In the absence of
data that would support a more precise
estimate, we will assume that 25 percent
of the 856 serious adverse event reports
for dietary supplements will have a
followup report submitted. FDA
requests comments on this estimate. We
estimate that each followup report will
require 1 hour to assemble and submit,
including the time needed to copy and
attach the initial serious adverse event
report as recommended in the draft
guidance. We assume the followup
report will take less time than the initial
serious adverse event report, as the
responsible person will not need to fill
out Form 3500A for the followup report.
FDA requests comments on whether the
burden estimate of 1 hour is reasonable
for this information collection. The
E:\FR\FM\15SEN1.SGM
15SEN1
53254
Federal Register / Vol. 73, No. 179 / Monday, September 15, 2008 / Notices
estimated total annual burden for
followup reports of new medical
information is shown in row 2 of table
1 of this document.
As previously noted, section 761(e)(1)
of the act requires that responsible
persons maintain records related to
dietary supplement adverse event
reports they receive, whether or not the
adverse event is serious. Under the
statute, the records must be retained for
a period of 6 years. The draft guidance
provides FDA’s recommendations as to
what records industry should maintain
to satisfy the statutory recordkeeping
requirement.
The guidance recommends that the
responsible person document its
attempts to obtain the minimum data
elements for a serious adverse event
report. Along with these records, the
guidance recommends that the
responsible person keep the following
other records: (1) Communications
between the responsible person and the
initial reporter of the adverse event and
with any other person(s) who provided
information about the adverse event; (2)
(for serious adverse events only) the
responsible person’s serious adverse
event report to FDA on MedWatch Form
3500A, with attachments; (3) any new
medical information about the adverse
event received by the responsible
person; (4) (for serious adverse events
only) any reports to FDA of new
medical information related to the
serious adverse event report. We
estimate that assembling and filing these
records, including any necessary
photocopying, will take approximately
0.5 hours per adverse event report
received by the responsible person.
Once the documents pertaining to an
adverse event report have been
assembled and filed, FDA expects the
records retention burden to be minimal,
as the agency believes most
establishments would normally keep
this kind of record for at least several
years after receiving the report, as a
matter of usual and customary business
practice. FDA requests comment on
current adverse event recordkeeping
practices in the dietary supplement
industry, including the length of time
such records are typically kept.
According to a 2001 report by the
Office of the Inspector General, between
1994–1999 FDA received 2,547 adverse
event reports involving dietary
supplements, or about 500 reports per
year, on average. According to the
report, the actual number of adverse
events relating to dietary supplements is
likely to be at least 100 times that many,
or more than 50,000 adverse events per
year. Given that we have limited data on
how many adverse events will be
reported each year to the responsible
person, we are using the 50,000 per year
figure as an upper-bound estimate of
reporting. This is almost certainly an
overestimate of the number of reports
the firms will receive, as it is unlikely
that every adverse event that occurs will
be reported to the responsible person.
FDA requests comments on this
estimate.
We estimated in the economic impact
analysis of the Dietary Supplement
Good Manufacturing Practices final rule
(the GMP final rule) (72 FR 34752, June
25, 2007) that there are 1,460
manufacturers, packers, and holders of
dietary supplements (72 FR 34752 at
34920). We assume that the estimated
50,000 adverse event reports related to
dietary supplements will be spread
evenly among these firms. The estimate
of the number of manufacturers,
packers, and holders of dietary
supplements from the GMP final rule is
FDA’s best estimate of the number of
firms that are ‘‘responsible persons’’
who must comply with the
recordkeeping requirements of the
DSNDCPA; however, it is not a precise
estimate because the number of dietary
supplement establishments covered by
the GMP final rule is likely to be larger
than the number of ‘‘responsible
persons,’’ where a ‘‘responsible person’’
is a dietary supplement manufacturer,
packer, or distributor whose name is
listed on the label of a dietary
supplement marketed in the United
States (see section 761(b)(1) of the act).
Thus, FDA’s estimate for the number of
respondents in table 2 may be over
inclusive. FDA requests comments on
the number of firms that would be
subject to the recordkeeping
requirements of the DSNDCPA.
The estimated total annual
recordkeeping burden under the statute
and this guidance is shown in table 2 of
this document.
TABLE 2—ESTIMATED ANNUAL RECORDKEEPING BURDEN1
No. of
Recordkeepers
Dietary supplement adverse event
records (21 U.S.C. 379aa–
1(e)(1))
Annual Frequency
per Recordkeeping
1,460
Total Annual
Records2
4.2465
Hours per
Record
50,000
Total Hours
0.5
25,000
1 There
are no capital costs or operating and maintenance costs associated with this collection of information.
2 For purposes of estimating the number of records and hours per record, a ‘‘record’’ means all records kept for an individual adverse event report received by the responsible person.
Dated: September 8, 2008.
Jeffrey Shuren,
Associate Commissioner for Policy and
Planning.
[FR Doc. E8–21454 Filed 9–12–08; 8:45 am]
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2008–N–0480]
BILLING CODE 4160–01–S
mstockstill on PROD1PC66 with NOTICES
Animal Drug User Fee Rates and
Payment Procedures for Fiscal Year
2009
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice.
SUMMARY: The Food and Drug
Administration (FDA) is announcing the
VerDate Aug<31>2005
20:22 Sep 12, 2008
Jkt 214001
PO 00000
Frm 00067
Fmt 4703
Sfmt 4703
rates and payment procedures for fiscal
year (FY) 2009 for user fees under the
Animal Drug User Fee Act program
(ADUFA). The Federal Food, Drug, and
Cosmetic Act (the act), as amended by
the Animal Drug User Fee Act of 2003
(ADUFA I), and the Animal Drug User
Fee Amendments of 2008 (ADUFA II),
authorizes FDA to collect user fees for
certain animal drug applications, on
certain animal drug products, on certain
establishments where such products are
made, and on certain sponsors of such
animal drug applications and/or
investigational animal drug
E:\FR\FM\15SEN1.SGM
15SEN1
Agencies
[Federal Register Volume 73, Number 179 (Monday, September 15, 2008)]
[Notices]
[Pages 53252-53254]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E8-21454]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA-2007-D-0372] (formerly Docket No. 2007D-0388)
Agency Information Collection Activities; Submission for Office
of Management and Budget Review; Comment Request; Adverse Event
Reporting and Recordkeeping for Dietary Supplements as Required by the
Dietary Supplement and Nonprescription Drug Consumer Protection Act
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The Food and Drug Administration (FDA) is announcing that a
proposed collection of information has been submitted to the Office of
Management and Budget (OMB) for review and clearance under the
Paperwork Reduction Act of 1995.
DATES: Fax written comments on the collection of information by October
15, 2008.
ADDRESSES: To ensure that comments on the information collection are
received, OMB recommends that written comments be faxed to the Office
of Information and Regulatory Affairs, OMB, Attn: FDA Desk Officer,
FAX: 202-395-6974, or e-mailed to baguilar@omb.eop.gov. All comments
should be identified with the OMB control number 0910-NEW and title,
``Adverse Event Reporting and Recordkeeping for Dietary Supplements as
Required by the Dietary Supplement and Nonprescription Drug Consumer
Protection Act.'' Also include the FDA docket number found in brackets
in the heading of this document.
FOR FURTHER INFORMATION CONTACT: Jonna Capezzuto, Office of
Information Management (HFA-710), Food and Drug Administration, 5600
Fishers Lane, Rockville, MD 20857, 301-796-3794.
SUPPLEMENTARY INFORMATION: In compliance with 44 U.S.C. 3507, FDA has
submitted the following proposed collection of information to OMB for
review and clearance.
Adverse Event Reporting and Recordkeeping for Dietary Supplements as
Required by the Dietary Supplement and Nonprescription Drug Consumer
Protection Act--(OMB Control Number 0910-NEW)
Description of Respondents: Respondents to this collection of
information are manufacturers, packers, and distributors of dietary
supplements marketed in the United States.
On December 22, 2006, the President signed into law the Dietary
Supplement and Nonprescription Drug Consumer Protection Act (DSNDCPA)
(Public Law 109-462, 120 Stat. 3469). This law amends the Federal Food,
Drug, and Cosmetic Act (the act) with respect to serious adverse event
reporting and recordkeeping for dietary supplements and non-
prescription drugs marketed without an approved application.
Under section 761(b)(1) of the act (21 U.S.C. 379aa-1(b)(1)), the
manufacturer, packer, or distributor whose name (under section
403(e)(1) of the act (21 U.S.C. 343(e)(1))) appears on the label of a
dietary supplement marketed in the United States is required to submit
to FDA any serious adverse event report it receives regarding use of
the dietary
[[Page 53253]]
supplement in the United States, accompanied by a copy of the product
label. In addition, under section 761(c)(2) of the act, the submitter
of the serious adverse event report (referred to in the statute as the
``responsible person'') is required to submit to FDA a followup report
of any related new medical information the responsible person receives
within 1 year of the initial report. Under section 761(e)(1) of the
act, responsible persons are required to maintain records related to
dietary supplement adverse event reports they receive, whether or not
the adverse event is serious. These requirements became effective on
December 22, 2007.
As required by section 3(d)(3) of the DSNDCPA, FDA is issuing
guidance to describe the minimum data elements for serious adverse
event reports for dietary supplements. The draft guidance entitled
``Questions and Answers Regarding Adverse Event Reporting and
Recordkeeping for Dietary Supplements as Required by the Dietary
Supplement and Nonprescription Drug Consumer Protection Act,'' was
issued October 15, 2007, and is consistent with FDA's good guidance
practices regulation (21 CFR 10.115). The draft guidance discusses how,
when, and where to submit serious adverse event reports for dietary
supplements and followup reports of new medical information. In
accordance with the statutory requirements that serious adverse event
reports for dietary supplements be submitted via MedWatch (section
761(d) of the act) and that FDA consolidate all information related to
a serious adverse event into a single report (section 761(c)(3) of the
act), the draft guidance directs the responsible person to submit
serious adverse event reports on MedWatch Form 3500A and to attach a
copy of the initial serious adverse event report on Form 3500A as part
of any followup report of new medical information. We are also
providing guidance on records maintenance and access for serious and
non-serious adverse event reports and related documents.
In the Federal Register of October 15, 2007 (72 FR 58313), FDA
published a 60-day notice requesting public comment on the information
collection provisions. FDA received one comment related to the
information collection. The comment disagreed with FDA's proposed
estimate of the annual recordkeeping burden associated with dietary
supplement adverse events. However, the commenter did not provide an
alternative estimate or compelling information that the estimate
provided by FDA was not a reasonable upper-bound estimate. Since the
receipt of the comment, the mandatory reporting of serious adverse
events for dietary supplements to FDA has come into effect (on December
22, 2007). Thus, FDA now has data on mandatory dietary supplement
adverse event reports to use in revising our reporting burden estimate.
For the first quarter of 2008 (January 1 to April 15), FDA has received
214 mandatory reports of serious adverse events related to dietary
supplements. Therefore, FDA revises our annual burden estimate from 960
mandatory reports to 856 mandatory reports of serious adverse events
related to dietary supplements. FDA requests comments on this estimate.
FDA estimates the burden of this collection of information as
follows:
Table 1--Estimated Annual Reporting Burden\1\
----------------------------------------------------------------------------------------------------------------
No. of Annual Frequency Total Annual Hours per
Respondents per Response Responses Response Total Hours
----------------------------------------------------------------------------------------------------------------
Serious adverse 71.3333 12 856 2 1,712
event reports
for dietary
supplements
(21 U.S.C.
379aa-1(b)(1))
----------------------------------------------------------------------------------------------------------------
Followup 17.83333 12 214 1 214
reports of new
medical
information
(21 U.S.C.
379aa-1(c)(2))
----------------------------------------------------------------------------------------------------------------
Total 1,926
----------------------------------------------------------------------------------------------------------------
\1\ There are no capital costs or operating and maintenance costs associated with this collection of
information.
FDA's Center for Drug Evaluation and Research estimates it will
take respondents a total of 2 hours to collect information about a
serious adverse event associated with an over-the-counter drug marketed
without an approved application and report the information to FDA on
MedWatch Form 3500A. That time burden estimate is based on FDA's
knowledge of the adverse drug experience reports submitted to the
agency for nonprescription drug products marketed under an approved
application, including knowledge about the time needed to prepare the
reports. FDA believes that the time for a dietary supplement firm to
collect information about a serious adverse event associated with a
dietary supplement and report the information to FDA will be
approximately the same, as MedWatch Form 3500A will be used in both
cases; therefore, we also estimate this time burden at 2 hours per
report. The estimated total annual burden for dietary supplement
serious adverse event reports is shown in row 1 of table 1 of this
document.
If a firm that has submitted a serious adverse event report
receives new medical information related to the serious adverse event
within 1 year of submitting the initial report, the firm must provide
the new medical information to FDA in a followup report. Given our
limited experience with mandatory dietary supplement adverse event
reporting, we do not have any information on the number of followup
reports of new medical information that will be submitted to FDA each
year. We expect followup medical information to be reported for some
percentage of the 856 serious adverse event reports we estimate
receiving annually. In the absence of data that would support a more
precise estimate, we will assume that 25 percent of the 856 serious
adverse event reports for dietary supplements will have a followup
report submitted. FDA requests comments on this estimate. We estimate
that each followup report will require 1 hour to assemble and submit,
including the time needed to copy and attach the initial serious
adverse event report as recommended in the draft guidance. We assume
the followup report will take less time than the initial serious
adverse event report, as the responsible person will not need to fill
out Form 3500A for the followup report. FDA requests comments on
whether the burden estimate of 1 hour is reasonable for this
information collection. The
[[Page 53254]]
estimated total annual burden for followup reports of new medical
information is shown in row 2 of table 1 of this document.
As previously noted, section 761(e)(1) of the act requires that
responsible persons maintain records related to dietary supplement
adverse event reports they receive, whether or not the adverse event is
serious. Under the statute, the records must be retained for a period
of 6 years. The draft guidance provides FDA's recommendations as to
what records industry should maintain to satisfy the statutory
recordkeeping requirement.
The guidance recommends that the responsible person document its
attempts to obtain the minimum data elements for a serious adverse
event report. Along with these records, the guidance recommends that
the responsible person keep the following other records: (1)
Communications between the responsible person and the initial reporter
of the adverse event and with any other person(s) who provided
information about the adverse event; (2) (for serious adverse events
only) the responsible person's serious adverse event report to FDA on
MedWatch Form 3500A, with attachments; (3) any new medical information
about the adverse event received by the responsible person; (4) (for
serious adverse events only) any reports to FDA of new medical
information related to the serious adverse event report. We estimate
that assembling and filing these records, including any necessary
photocopying, will take approximately 0.5 hours per adverse event
report received by the responsible person.
Once the documents pertaining to an adverse event report have been
assembled and filed, FDA expects the records retention burden to be
minimal, as the agency believes most establishments would normally keep
this kind of record for at least several years after receiving the
report, as a matter of usual and customary business practice. FDA
requests comment on current adverse event recordkeeping practices in
the dietary supplement industry, including the length of time such
records are typically kept.
According to a 2001 report by the Office of the Inspector General,
between 1994-1999 FDA received 2,547 adverse event reports involving
dietary supplements, or about 500 reports per year, on average.
According to the report, the actual number of adverse events relating
to dietary supplements is likely to be at least 100 times that many, or
more than 50,000 adverse events per year. Given that we have limited
data on how many adverse events will be reported each year to the
responsible person, we are using the 50,000 per year figure as an
upper-bound estimate of reporting. This is almost certainly an
overestimate of the number of reports the firms will receive, as it is
unlikely that every adverse event that occurs will be reported to the
responsible person. FDA requests comments on this estimate.
We estimated in the economic impact analysis of the Dietary
Supplement Good Manufacturing Practices final rule (the GMP final rule)
(72 FR 34752, June 25, 2007) that there are 1,460 manufacturers,
packers, and holders of dietary supplements (72 FR 34752 at 34920). We
assume that the estimated 50,000 adverse event reports related to
dietary supplements will be spread evenly among these firms. The
estimate of the number of manufacturers, packers, and holders of
dietary supplements from the GMP final rule is FDA's best estimate of
the number of firms that are ``responsible persons'' who must comply
with the recordkeeping requirements of the DSNDCPA; however, it is not
a precise estimate because the number of dietary supplement
establishments covered by the GMP final rule is likely to be larger
than the number of ``responsible persons,'' where a ``responsible
person'' is a dietary supplement manufacturer, packer, or distributor
whose name is listed on the label of a dietary supplement marketed in
the United States (see section 761(b)(1) of the act). Thus, FDA's
estimate for the number of respondents in table 2 may be over
inclusive. FDA requests comments on the number of firms that would be
subject to the recordkeeping requirements of the DSNDCPA.
The estimated total annual recordkeeping burden under the statute
and this guidance is shown in table 2 of this document.
Table 2--Estimated Annual Recordkeeping Burden\1\
----------------------------------------------------------------------------------------------------------------
No. of Annual Frequency Total Annual
Recordkeepers per Recordkeeping Records\2\ Hours per Record Total Hours
----------------------------------------------------------------------------------------------------------------
Dietary 1,460 4.2465 50,000 0.5 25,000
supplement
adverse event
records (21
U.S.C. 379aa-
1(e)(1))
----------------------------------------------------------------------------------------------------------------
\1\ There are no capital costs or operating and maintenance costs associated with this collection of
information.
\2\ For purposes of estimating the number of records and hours per record, a ``record'' means all records kept
for an individual adverse event report received by the responsible person.
Dated: September 8, 2008.
Jeffrey Shuren,
Associate Commissioner for Policy and Planning.
[FR Doc. E8-21454 Filed 9-12-08; 8:45 am]
BILLING CODE 4160-01-S